drugset / Trial / NCT07600554
A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The aim of this study is to assess the safety and dosimetry of imaging with \[68Ga\]Ga-OncoACP3 in patients with prostate cancer.
Timeline
- Start
- 2026-05-27
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [68Ga]Ga-OncoACP3 | Diagnostic / imaging agent | 250 mbq | Intravenous |